Literature DB >> 2442246

Generation of lymphokine-activated killer cell activity from human thymocytes.

F J Ramsdell, S H Golub.   

Abstract

We have generated lymphokine-activated killer (LAK) cells from human thymocytes in order to assess the relationship between LAK cells and T cells. Fresh thymocytes lack natural cytotoxic activity, and cytotoxicity cannot be stimulated by short term (1 hr) incubation with interferon or recombinant interleukin 2 (rIL-2). In addition, thymocytes are phenotypically devoid of cells bearing the natural killer (NK)-associated markers cluster designation (CD) 16 and NKH-1. After culture for 5 to 8 days with rIL-2, thymocytes display high levels of cytotoxic activity against both NK-sensitive and NK-resistant targets. Thymocytes require slightly more IL-2 than do peripheral blood lymphocytes to generate LAK activity. We have examined the phenotype of the thymocyte LAK precursor and effector cells. Thymocyte LAK precursors are of low to medium density, CD1-negative, and predominantly CD3-negative. Although CD3-positive cells proliferate in response to rIL-2, they are low in cytolytic capabilities. The effector cells, like the LAK precursors, are low to medium density lymphocytes. The cytotoxic cells are predominantly CD3-negative, and cytotoxic activity cannot be blocked with the use of anti-CD3 monoclonal antibodies. The effector cells also lack most NK-associated markers (HNK-1, and the CD16 markers Leu-11b and B73.1) but possess the NK-associated marker NKH-1 (N901). The responsive cell appears to be at a very early stage of thymic development, and it does not appear to either require or express the CD3-T cell receptor complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.

Authors:  T Y Chao; H Ohnishi; T M Chu
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

2.  Herpes simplex virus-infected cells disarm killer lymphocytes.

Authors:  D L Confer; G M Vercellotti; D Kotasek; J L Goodman; A Ochoa; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood.

Authors:  J A Kummer; A M Kamp; T M Tadema; W Vos; C J Meijer; C E Hack
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2.

Authors:  E Weidmann; L Bergmann; P Hechler; P S Mitrou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Immunopathological features of human pulmonary tumors following low-dose interleukin-2.

Authors:  S G Swisher; T M Anderson; D R Wen; M A Stene; A J Cochran; S H Golub; E C Holmes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Role of proliferation in LAK cell development.

Authors:  F J Ramsdell; H Shau; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Resistance of cytolytic lymphocytes to perforin-mediated killing. Lack of correlation with complement-associated homologous species restriction.

Authors:  S B Jiang; P M Persechini; A Zychlinsky; C C Liu; B Perussia; J D Young
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

8.  The heterogeneity of target recognition by lymphokine-activated killer precursor cells.

Authors:  Y Ibayashi; J D Gray; S H Golub; M Daibo; T Yamaki; T Kawahara; T Kubota; K Hashi
Journal:  Jpn J Cancer Res       Date:  1990-09

9.  Human natural killer cell committed thymocytes and their relation to the T cell lineage.

Authors:  M J Sánchez; H Spits; L L Lanier; J H Phillips
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.